Background Adjuvant immunotherapy with autologous cytokine-induced killer (CIK) cells
has shown promise postsurgery, yet research concerning hepatocellular carcinoma (HCC) …

Background Studies using data from randomized controlled trials (RCTs) and real-world
data (RWD) have suggested that adjuvant cytokine-induced killer (CIK) cell immunotherapy …

Background & Aims No adjuvant therapy has been shown to extend the survival of patients
with hepatocellular carcinoma (HCC) receiving curative treatment. We investigated whether …

Our earlier multicenter randomized controlled trial showed that adjuvant immunotherapy
with cytokine-induced killer (CIK) cells resulted in longer recurrence-free survival (RFS) and …

Background Several randomized controlled trials have shown that adjuvant immunotherapy
with autologous cytokine-induced killer (CIK) cells prolongs recurrence-free survival (RFS) …

This study was designed to evaluate the efficacy and safety of cytokine-induced killer (CIK)
cell-based immunotherapy as an adjuvant therapy for hepatocellular carcinoma (HCC) …

ABSTRACT Background & Aims: There is no generally accepted adjuvant therapy for
hepatocellular carcinoma (HCC) after curative resection. Autologous cytokine-induced killer …

In attempts to delay tumor progression after surgery or minimally invasive local treatments,
multidisciplinary strategies have been broadly studied in patients with hepatocellular …

Background High recurrence rate after curative treatment is the major problem for
hepatocellular carcinoma (HCC). Cytokine-induced killer cells (CIKs) therapy was …

The benefits of adjuvant cytokine-induced killer (CIK) cell immunotherapy for hepatocellular
carcinoma (HCC) remain mixed among patients. Here, we constructed a prognostic …